Literature DB >> 16966149

Photodynamic therapy of experimental choroidal neovascularization in the mouse.

Anne Odergren1, Yue Ming, Anders Kvanta.   

Abstract

PURPOSE: To evaluate the qualitative and quantitative effects of verteporfin photodynamic therapy (PDT) on laser-induced choroidal neovascularization (CNV) in the mouse.
METHODS: PDT was applied to the normal mouse fundus using light doses of 32, 64, and 83 s, and histological analysis of the treated areas was performed. CNV was induced using krypton laser photocoagulation of the fundus, and the CNV lesions were subsequently treated with PDT using light doses of 32, 64, and 83 s. Enucleated eyes were analyzed with light and transmission electron microscopies, and measurements of CNV size were done on histologic sections and on isolectin B4-stained choroidal flat mounts.
RESULTS: PDT induced a light dose-dependent damage to the surrounding neural retina in normal eyes. At a light dose of 32 s, minimal damage was detected in the neural retina, whereas higher light doses caused distortion and disruption of the outer and inner nuclear layers and of the retinal pigment epithelium. When PDT was applied over laser-induced CNV lesions, the relative height of the lesions was significantly reduced (p < 0.05) using all light doses. Transmission electron microscopy 1 day after PDT treatment revealed occlusion of many of the CNV vessels. One week after PDT treatment, the CNV lesions contained patent vessels irrespective of light dose applied. Accordingly, PDT treatment inhibited (p < 0.05) but did not halt CNV lesion growth.
CONCLUSIONS: PDT treatment of laser-induced CNV may create an acute occlusion of neovessels and an inhibition of CNV lesion growth without apparent injury to the surrounding neural retina. However, PDT-treated areas will remain vascularized with continued growth of the CNV lesion, which in turn may explain the often limited effect of PDT in patients with neovascular age-related macular degeneration. Elevating the PDT light dose will not increase the treatment effect substantially but may lead to increased collateral injury.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16966149     DOI: 10.1080/02713680600865045

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  7 in total

1.  Association of ARMS2/HTRA1 variants with polypoidal choroidal vasculopathy phenotype in a Korean population.

Authors:  Dong Ho Park; In Taek Kim
Journal:  Jpn J Ophthalmol       Date:  2011-09-29       Impact factor: 2.447

Review 2.  LOC387715/HTRA1 gene polymorphisms and susceptibility to age-related macular degeneration: A HuGE review and meta-analysis.

Authors:  Yu Tong; Jing Liao; Yuan Zhang; Jing Zhou; Hengyu Zhang; Meng Mao
Journal:  Mol Vis       Date:  2010-10-05       Impact factor: 2.367

3.  Anti-angiogenic effects of non-peptide integrin alphavbeta3 specific antagonist on laser-induced choroidal neovascularization in mice.

Authors:  Shigeru Honda; Takayuki Nagai; Akira Negi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-12-02       Impact factor: 3.117

4.  Ranibizumab in the treatment of choroidal neovascularization on the border of an inferior staphyloma associated with tilted disc syndrome.

Authors:  Luis Arias; Jordi Monés
Journal:  Clin Ophthalmol       Date:  2010-04-26

5.  The use of Matrigel combined with encapsulated cell technology to deliver a complement inhibitor in a mouse model of choroidal neovascularization.

Authors:  Balasubramaniam Annamalai; Nathaniel Parsons; Carlene Brandon; Bärbel Rohrer
Journal:  Mol Vis       Date:  2020-05-15       Impact factor: 2.367

6.  Verteporfin-mediated on/off photoswitching functions synergistically to treat choroidal vascular diseases.

Authors:  Yahan Ju; Xiaochan Dai; Zhimin Tang; Zunzhen Ming; Ni Ni; Dongqing Zhu; Jing Zhang; Bo Ma; Jiajing Wang; Rui Huang; Siyu Zhao; Yan Pang; Ping Gu
Journal:  Bioact Mater       Date:  2022-02-01

7.  Choroidal neovascularization reduced by targeted drug delivery with cationic liposome-encapsulated paclitaxel or targeted photodynamic therapy with verteporfin encapsulated in cationic liposomes.

Authors:  Nikolai Gross; Mahdy Ranjbar; Charlotte Evers; Jing Hua; Gottfried Martin; Brita Schulze; Uwe Michaelis; Lutz L Hansen; Hansjürgen T Agostini
Journal:  Mol Vis       Date:  2013-01-10       Impact factor: 2.367

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.